• Baden (BDN) informs of an update on the transaction with Northstar Gaming Inc
  • The companies have agreed to amend the terms of their business combination to extend the outside date for completion 
  • NorthStar has raised $10,075,000 for the completion of the proposed transaction
  • The company will continue to raise capital in the future
  • Baden Resources is a mineral exploration company in British Columbia
  • Baden Resources (BDN) is unchanged on the day, trading at C$0.20 at 1:25 pm EST.

Baden Resources (BDN) made some changes to its previously announced proposed reverse takeover.

Baden and NorthStar have agreed to amend the terms of their business combination to extend the outside date to January 30, 2023.

On November 23, 2022, Baden held an annual and special shareholders’ meeting in which all shareholder resolutions necessary to complete the proposed transaction were approved.

NorthStar has managed to raise $10,075,000 to complete the proposed transaction.

NorthStar is continuing its efforts to raise additional funds.

Both companies are continuing to work towards satisfying all conditions of closing the transaction

Baden Resources is a mineral exploration company focused on the acquisition, exploration, and development of mineral properties in British Columbia.

Baden Resources (BDN) is unchanged on the day, trading at C$0.20 at 1:25 pm EST. 


More From The Market Online

ESE producing championship e-sports tournament for Riot Games

ESE Entertainment’s (TSXV:ESE) media production unit, Frenzy, takes on the distribution of the upcoming Teamfight Tactics e-sports tournament.

York Harbour Metals reveals more promising rare earth sampling assays

York Harbour Metals (TSXV:YORK) reports encouraging findings in its latest Bottom Brook Rare Earth Elements project analysis.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.